• Protecting Antibody IP Across Continents
• Improving Selection and Libraries
• Solving Antibody Problems: Aggregation, Glycosylation, and Delivery
• Engineering for Optimum Performance and Yield
• Emerging Technologies: The Next Generation
• Applications and Case Studies

Scientific Advisors

Arne Skerra, Ph.D., Technical University of Munich

Stefan Goletz, Ph.D., GLYCOTOPE

Hennie Hoogenboom, Ph.D., Ablynx

Lutz Jermutus, Ph.D., Cambridge Antibody Technologies/AZ

Protecting and Enforcing the Intellectual Property of Antibodies in Europe and the US
Veronica Mullally, Partner, Intellectual Property, Orrick, Herrington & Sutcliffe LLP

In Vitro Selection and Characterization of DARPins and Fab Fragments for the Co-Crystallization of Membrane Proteins
Thomas Huber, MSc., Laboratory of Prof. A. Plueckthun, Department of Biochemistry, University of Zurich

Method for Generation of Human Hyperdiversified Antibody Fragment Library
Philippe Mondon, Ph.D., Department of Molecular Evolution and Department of Bioinformatics, MilleGen SA

A Cell-Based Approach for the Biosynthesis/Screening of Cyclotide-Based Libraries against Bacterial Toxins
Julio A. Camarero, Staff Scientist, Head of Lab, Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory

Glyco-Optimized Rituximab Produced Has Enhanced ADCC Activity 
Lynn Dickey, Ph.D, VP of Research and Technology Development, Research & Technology Development, Biolex Therapeutics

Glycosylation of an Immunoglobulin Produced from a Murine Hybridoma Cell Line: The Effect of Culture Mode and the Anti-Apoptotic Gene, bcl-2
Mohamed Al-Rubeai, Ph.D., Department of Chemical Engineering, University of Birmingham (Invited)

Generation of Glycan Optimized IgGs in Glycoengineered Plants
Herta Steinkellner, M.D., Ph.D, Dr., Institute of Applied Genetics and Cell Biology, Agricultural University Vienna

Advanced Technology for the Next Generation of Monoclonal Antibodies 
Masahiro Tomita, Ph.D, Professor, Division of Chemistry for Materials, Graduate School of Engineering, Mie University

Next Generation Antibodies with Enhanced Effector Functions 
Ekkehard Mössner, Ph.D, Senior Scientist, Antibody Engineering, Glycart Biotechnology

Overcoming Adverse Immunogenicity against Therapeutic Proteins for the Treatment of Cancer 
Matthew Baker, Ph.D, CSO, R&D, Antitope

Plant Seeds as Bioreactor for the Production of scFv-Fc Antibody Variants
Ann Depicker, Ph.D., Department of Plant Systems Biology, Flanders Institute for Biotechnology, Ghent University

Phylomers: Synthetic Peptides Derived from Protein Fragments Suitable for Intracellular as Well as Extracellular Targets
Paul Watt, Ph.D, Vice President, Drug Discovery, Phylogica Ltd.

Moving Beyond Antibodies: Anticalins®, A Novel Class of Therapeutic Proteins 
Andreas Hohlbaum, Ph.D, Dir. of Science and Preclinical Development, R&D, Pieris AG

DARPins for Targeted Tumor Therapy and Diagnosis 
Kaspar Binz, Ph.D, Executive Director, Research, Molecular Partners

Aptamers - An Antibody Alternative
Anthony Keefe, Ph.D, Senior Principal Investigator, Aptamer Discovery, Archemix Corp.

Tumor Targeting with Chimeric Heavy Chain Antibodies 
Jianbing Zhang, Ph.D., Research Officer, Institute for Biological Sciences, National Research Council

Single Chain Fab (scFab) Fragment and Human Targeted RNases
Stefan Dübel, Ph.D., Director, Dept. of Biotechnology, Technical University of Braunschweig

Antibodies as Protease Inhibitors
Laetitia Devy, Ph.D., Principal scientist, Cell Biology, Dyax sa

Adecatumumab: A Human Antibody for Tumor Therapy 
Tobias Raum, Ph.D., Director, Immunotherapy, Micromet AG